Evaluation of PARVG located on 22q13 as a candidate tumor suppressor gene for colorectal and breast cancer

被引：14

作者：

Castellví-Bel, S

Castells, A ^{[1
]}

Johnstone, CN

Piñol, V

Pellisé, M

Elizalde, JI

Romo, N

Rustgi, AK

Piqué, JM

机构：

[1] Hosp Clin Barcelona, Inst Malalties Digest, Dept Gastroenterol, Barcelona, Catalonia, Spain

[2] Univ Penn, Dept Gastroenterol, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[3] Univ Penn, Dept Genet, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[4] Univ Penn, Family Canc Res Inst, Philadelphia, PA 19104 USA

来源：

CANCER GENETICS AND CYTOGENETICS | 2003年 / 144卷 / 01期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1016/S0165-4608(03)00034-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Colorectal cancer (CRC) and breast cancer constitute common neoplasms in Western countries and leading causes of cancer-related death. Development and progression of both malignancies occur as a multistep process, requiring the activation of oncogenes and the inactivation of several tumor suppressor genes. Our group has recently identified a minimal region of deletion on 22q13 involved in CRC and breast cancer patients, which is highly indicative of the existence of a tumor suppressor gene (or genes). We performed mutation analysis of the PARVG gene, one of the genes present on the 22q13 region of interest, which has been previously demonstrated to have a reduced expression in some cancer cell lines. We have identified several DNA variants that are not compatible with pathogenic mutations. Accordingly, PARVG appears not to be a tumor suppressor gene involved in CRC and breast cancer development and progression. (C) 2003 Elsevier Inc. All rights reserved.

引用

页码：80 / 82

页数：3

共 11 条

[1]

[Anonymous], 2002, MOL BASIS HUMAN CANC

[2] DNA hypermethylation in tumorigenesis - epigenetics joins genetics [J].